Press release
Oligonucleotide Therapeutics Market Players Regulus Therapeutics, Ionis Pharmaceuticals, Gilead, Santaris, InteRNA
Oligonucleotides are short chain RNA or DNA which are usually manufactured by utilizing automated synthesizers. Purification of the oligonucleotide is done by anion exchange chromatography which is followed by desalting and freezing technique. For the synthesis of siRNA duplex oligonucleotide, an annealing step is carried out where two purified oligonucleotide strands are brought together in an equimolar ratio.Oligonucleotide therapeutics are different from conventional medicine as they can inhibit the expression of certain genes. This has given rise to innovative new oligonucleotides that can target specific genes and treat chronic diseases. The development of oligonucleotide therapeutics is done through chemically modified artificial nucleic acids. The artificial oligonucleotides are being developed which has improved in vivo stability and enhanced affinity to target mRNA.
Request Report Sample@ https://www.persistencemarketresearch.com/samples/12787
Oligonucleotide Therapeutics Market: Dynamics
The demand for oligonucleotides is expected to upsurge as there are very few approved molecules. This has offered oligonucleotide market players a wide scope to discover new molecular entities. Moreover, the technology upgrades of chemically synthesized oligonucleotides have led to the development of more stable and extended half-life molecules. There are around 135 oligonucleotide therapeutics currently in different stages of drug development, which may further add to the limited three approved drugs currently available in the oligonucleotide therapeutics market.
Oligonucleotide Therapeutics Market: Segmentation
On the basis of application, the oligonucleotide therapeutics market can be segmented as:
Infectious diseases
Oncology
Neurodegenerative disorders
Cardiovascular diseases
Kidney diseases
Others
The area of treatment with oligonucleotides is wide and offers promising results. Oligonucleotides have a distinguishing feature as compared to small molecule and protein therapeutics in that it can directly affect the protein targets. Specific RNA interference at the cellular level and targeting malfunctioning gene to suppress, manipulate or silence can all be done via oligonucleotides therapeutics.
On the basis of type, the oligonucleotide therapeutics market can be segmented as:
Antisense
Ribozymes
Aptamers
miRNA
CpG/Immunostimulatory
RNAi
The number of oligonucleotides in the clinical pipeline is small compared to other therapeutic classes, but still, the clinical movement of these molecules is increasing. From 2012 to 2015, the biggest increase in oligonucleotides clinical phase was from Phase 1 to Phase 2. By mid-2015, the number of oligonucleotides in Phase 2 almost doubled than that in Phase 1, indicating that the pipeline is maturing.
Oligonucleotide Therapeutics Market: Region-wise Outlook
The presence of the main market leaders, market consolidation and commercialization of new molecules are all contributing towards the dominating position of North America in the oligonucleotides therapeutic market. Miragen Therapeutics, Inc. agreed to merge with Signal Genetics, Inc for an initial investment of USD 40 million. Through this merger both the companies expect to develop micro RNA-targeted oligonucleotide clinical products. New molecule application is also another strategy the market players are using to mark their presence in the oligonucleotide therapeutic market. Biogen recently received FDA approval for a new drug application for nusinersen. If approved, the antisense oligonucleotides molecule would be the first of its kind to be used for treating spinal muscular atrophy.
Asia-Pacific is the fastest growing region as several oligonucleotide therapeutics manufacturers are looking forward to establishing manufacturing facilities in this region. Moreover, research undertaking and funding in the synthesis of oligonucleotides are expected to add on to the increasing demand. Recently, Daiichi Sankyo Co., Ltd. announced its intention to open up a new company named Orphan Disease Treatment Institute Co., Ltd. to treat Duchenne muscular dystrophy through its active ingredient ENA oligonucleotide. The company is a collaboration between Daiichi, Mitsubishi UFJ Capital Co., Ltd. and Innovation Network Corporation of Japan and looks forward to entering the oligonucleotide therapeutics market.
Oligonucleotide Therapeutics Market: Market Players
One of the major trends driving the oligonucleotides therapeutic market is the increasing licensing and collaboration activities. Moreover, the demand for advanced technologies in oligonucleotide therapeutics such as gene silencing through RNAi is gaining importance due to its high efficiency, thereby propelling the oligonucleotide therapeutics market.
Some of the key contributors to the oligonucleotide therapeutics market are PCI Biotech, SomaGenics, ContraVir, Alnylam, Regulus Therapeutics, Ionis Pharmaceuticals, Gilead, Santaris, InteRNA, miRage, Biogen, Merck and Pfizer, among others.
Visit For TOC@ https://www.persistencemarketresearch.com/toc/12787
About Us
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.
To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.
Contact Us
Persistence Market Research
305 Broadway
7th Floor, New York City,
NY 10007, United States,
Telephone - +1-646-568-7751
USA – Canada Toll Free: 800-961-0353
Email: sales@persistencemarketresearch.com
Web: http://www.persistencemarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Oligonucleotide Therapeutics Market Players Regulus Therapeutics, Ionis Pharmaceuticals, Gilead, Santaris, InteRNA here
News-ID: 1515851 • Views: …
More Releases from Persistence Market Research

North America Wiring Devices Market Projected to Reach USD 26.46 Billion by 2031
Overview of the North America Wiring Devices Market
The North America wiring devices market is poised for steady growth over the forecast period, with its size estimated at US$ 18.96 billion in 2024, projected to reach US$ 26.46 billion by 2031, reflecting a CAGR of 4.9%. The market is witnessing substantial expansion due to increasing urbanization, a rising number of residential and commercial construction projects, and the adoption of energy-efficient and…

Global Forged Automotive Components Market Poised for Steady Growth, Projected t …
The global forged automotive components market is on a robust growth trajectory, currently valued at approximately US$ 50.3 billion in 2025 and forecasted to expand to US$ 70.7 billion by the end of 2032. This growth represents a compound annual growth rate (CAGR) of 5.0% over the coming decade, driven by increasing automotive production, technological advancements, and evolving consumer preferences toward durable, high-performance vehicle parts.
Forged automotive components are critical to…

Global Electric Cargo Bike Market Set to Accelerate at 11.9% CAGR, Reaching US$ …
The global electric cargo bike market is set to experience substantial growth over the coming decade, with Persistence Market Research (PMR) forecasting a compound annual growth rate (CAGR) of 11.9% from 2023 through 2032. Valued at approximately US$ 800 million in 2021, the market is expected to surge to a projected valuation of US$ 2.14 billion by the end of 2032. Notably, electric cargo bikes accounted for 66.2% of the…

Bicycle Bearings Market Set for Steady Growth with 6.5% CAGR Through 2032, Drive …
The global bicycle bearings market is poised for significant expansion over the forecast period of 2025 to 2032, according to the latest report released by Persistence Market Research. Valued at approximately US$ 5.99 billion in 2024, the market is projected to reach US$ 6.35 billion by 2025 and further escalate to nearly US$ 9.86 billion by 2032. This growth trajectory reflects a compound annual growth rate (CAGR) of 6.5%, underscoring…
More Releases for Oligonucleotide
Increasing Cancer Epidemic Driving Growth In The Oligonucleotide Therapy Market: …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Oligonucleotide Therapy Market Size Growth Forecast: What to Expect by 2025?
The market size for oligonucleotide therapy has been swiftly expanding in the past few years. Projected growth is from $5.61 billion in 2024 to $6.2 billion in 2025, indicating a compound annual growth rate (CAGR) of 10.5%. The…
Oligonucleotide Synthesis Market CAGR 9.9% by 2035, Due To The Growing Demand Fo …
According to our latest market report "Oligonucleotide Synthesis Market by Application Area, Type of Product Synthesized, Type of Oligonucleotide Synthesized, Scale of Operation, Therapeutic Area, End-users, Company Size and Key Geographical Regions: Industry Trends and Global Forecasts, Till 2035", the global oligonucleotide synthesis market size is projected to reach USD 13.5 billion by 2035 from USD 4.8 billion in 2024, growing at a CAGR of 9.9% in the forecast period…
Oligonucleotide Synthesis Market Outlook, 2030
The global oligonucleotide synthesis market is set to witness unprecedented growth in the coming decade, driven by advancements in biotechnology, increasing applications in genetic research, and rising demand for personalized medicine. According to market research, the global oligonucleotide synthesis market size was valued at USD 5.198 billion in 2020 and is projected to reach USD 26.09 billion by 2030, growing at a compound annual growth rate (CAGR) of 17.10% from…
Antisense Oligonucleotide Therapeutics Market
Antisense Oligonucleotide Therapeutics Market worth $ 64.64 Billion by 2030 - Exclusive Report by Insight Analytics
Insight Analytics Pvt. Ltd. announces the release of a market assessment report on the "Global Antisense Oligonucleotide Therapeutics Market- by Therapy (Monotherapy and Combination), Molecule Target Indication (DNA Molecule and RNA Molecule), Target Indication (Duchenne Muscular Atrophy, Spinal Muscular Atrophy, Familial Chylomicronemia Syndrome, Amyotrophic Lateral Sclerosis, Familial Partial Lipodystrophy, Hereditary Transthyretin-Mediated (hatter) Amyloidosis, Huntington's Disease…
Oligonucleotide Therapy Market Transforming Healthcare: The Oligonucleotide Ther …
Oligonucleotide Therapy Market worth $19.92 Bn by 2031 - Exclusive Report by InsightAce Analytic Pvt. Ltd.
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Oligonucleotide Therapy Market - (By Type (Antisense, Ribozymes, Aptamers, miRNA, CpG/Immunostimulatory, RNAi), By Application (Infectious Diseases, Oncology, Neurodegenerative Disorders, Cardiovascular Diseases, Kidney Diseases, Others), By End User
(Hospitals, Research Institutes, Others)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
According…
Global Market Study on Oligonucleotide Synthesis: Custom Oligonucleotide Synthes …
Researchmoz added latest report "Global Market Study on Oligonucleotide Synthesis: Custom Oligonucleotide Synthesis Service Type Segment to Hold 70% Market Share by 2025". The industry report lists the leading competitors and provides the insights strategic industry Analysis of the key factors influencing the market.
Our new research report on the global oligonucleotide synthesis market gives a brief overview of the global market. The report includes projections on the global oligonucleotide synthesis…